157 related articles for article (PubMed ID: 32324216)
1. IKBKE activity enhances AR levels in advanced prostate cancer via modulation of the Hippo pathway.
Bainbridge A; Walker S; Smith J; Patterson K; Dutt A; Ng YM; Thomas HD; Wilson L; McCullough B; Jones D; Maan A; Banks P; McCracken SR; Gaughan L; Robson CN; Coffey K
Nucleic Acids Res; 2020 Jun; 48(10):5366-5382. PubMed ID: 32324216
[TBL] [Abstract][Full Text] [Related]
2. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
4. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
5. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells.
Zhang L; Yang S; Chen X; Stauffer S; Yu F; Lele SM; Fu K; Datta K; Palermo N; Chen Y; Dong J
Mol Cell Biol; 2015 Apr; 35(8):1350-62. PubMed ID: 25645929
[TBL] [Abstract][Full Text] [Related]
6. IKBKE regulates cell proliferation and epithelial-mesenchymal transition of human malignant glioma via the Hippo pathway.
Lu J; Yang Y; Guo G; Liu Y; Zhang Z; Dong S; Nan Y; Zhao Z; Zhong Y; Huang Q
Oncotarget; 2017 Jul; 8(30):49502-49514. PubMed ID: 28548934
[TBL] [Abstract][Full Text] [Related]
7. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer.
Nadiminty N; Tummala R; Liu C; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2015 Aug; 14(8):1884-95. PubMed ID: 26056150
[TBL] [Abstract][Full Text] [Related]
8. Wnt signaling promotes androgen-independent prostate cancer cell proliferation through up-regulation of the hippo pathway effector YAP.
Seo WI; Park S; Gwak J; Ju BG; Chung JI; Kang PM; Oh S
Biochem Biophys Res Commun; 2017 May; 486(4):1034-1039. PubMed ID: 28366633
[TBL] [Abstract][Full Text] [Related]
9. Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
Hinneh JA; Gillis JL; Mah CY; Irani S; Shrestha RK; Ryan NK; Atsushi E; Nassar ZD; Lynn DJ; Selth LA; Kato M; Centenera MM; Butler LM
Br J Cancer; 2023 Oct; 129(8):1350-1361. PubMed ID: 37673961
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo.
Thomas C; Zoubeidi A; Kuruma H; Fazli L; Lamoureux F; Beraldi E; Monia BP; MacLeod AR; Thüroff JW; Gleave ME
Mol Cancer Ther; 2011 Feb; 10(2):347-59. PubMed ID: 21216933
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
12. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
14. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
15. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
16. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells.
Vander Griend DJ; Antony L; Dalrymple SL; Xu Y; Christensen SB; Denmeade SR; Isaacs JT
Mol Cancer Ther; 2009 May; 8(5):1340-9. PubMed ID: 19417145
[TBL] [Abstract][Full Text] [Related]
17. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma controls prostate cancer cell growth through AR-dependent and independent mechanisms.
Elix CC; Salgia MM; Otto-Duessel M; Copeland BT; Yoo C; Lee M; Tew BY; Ann D; Pal SK; Jones JO
Prostate; 2020 Feb; 80(2):162-172. PubMed ID: 31769890
[TBL] [Abstract][Full Text] [Related]
19. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.
Fernandez EV; Reece KM; Ley AM; Troutman SM; Sissung TM; Price DK; Chau CH; Figg WD
Mol Pharmacol; 2015 Jun; 87(6):1006-12. PubMed ID: 25829060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
